Browse

Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas

Cited 244 time in Web of Science Cited 269 time in Scopus
Authors
Joo, Kyeung Min; Kim, Shi Yean; Jin, Xun; Song, Sang Yong; Kong, Doo-Sik; Lee, Jung-Ii; Jeon, Ji Won; Kim, Mi Hyun; Kang, Bong Gu; Jung, Yong; Jin, Juyoun; Hong, Seung-Chyul; Park, Woong-Yang; Lee, Dong-Sup; Kim, Hyunggee; Nam, Do-Hyun
Issue Date
2008-06-16
Publisher
Nature Publishing Group
Citation
Lab Invest. 2008;88(8):808-815
Keywords
AdultAgedAged, 80 and overAnimalsAntigens, CD/*metabolismBrain/pathologyBrain Neoplasms/*immunology/pathologyCells, CulturedDrug Resistance, Neoplasm/immunologyFemaleGene Expression ProfilingGlioblastoma/*immunology/pathologyGlycoproteins/*metabolismHumansMaleMiceMice, SCIDMiddle AgedNeoplastic Stem Cells/*immunologyPeptides/*metabolism
Abstract
A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential. These findings raise an attractive hypothesis that GBMs can be cured by eradicating CD133-positive cancer stem cells (CSCs), which are a small portion of GBM cells. However, as GBMs are known to possess various genetic alterations, GBMs might harbor heterogeneous CSCs with different genetic alterations. Here, we compared the clinical characteristics of two GBM patient groups divided according to CD133-positive cell ratios. The CD133-low GBMs showed more invasive growth and gene expression profiles characteristic of mesenchymal or proliferative subtypes, whereas the CD133-high GBMs showed features of cortical and well-demarcated tumors and gene expressions typical of proneuronal subtype. Both CD133-positive and CD133-negative cells purified from four out of six GBM patients produced typical GBM tumor masses in NOD-SCID brains, whereas brain mass from CD133-negative cells showed more proliferative and angiogenic features compared to that from CD133-positive cells. Our results suggest, in contrast to previous reports that only CD133-positive cells of GBMs can initiate tumor formation in vivo CD133-negative cells also possess tumor-initiating potential, which is indicative of complexity in the identification of cancer cells for therapeutic targeting.
ISSN
1530-0307 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18560366

http://www.nature.com/labinvest/journal/v88/n8/pdf/labinvest200857a.pdf

http://hdl.handle.net/10371/67688
DOI
https://doi.org/10.1038/labinvest.2008.57
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Anatomy (해부학전공)Journal Papers (저널논문_해부학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse